Advertisement

U.S. Markets closed

S&P Futures
5,909.50
+3.50(+0.06%)
Dow Futures
43,551.00
+33.00(+0.08%)
Nasdaq Futures
20,490.75
+7.25(+0.04%)
Russell 2000 Futures
2,294.80
+3.60(+0.16%)
Crude Oil
69.58
+0.36(+0.52%)
Gold
2,747.20
+17.20(+0.63%)

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

46.41

+0.16

(+0.35%)

At close: 04:00PM EDT

47.48

+1.07

(+2.31%)

After hours:

07:00PM EDT

Trade prices are not sourced from all markets

All

Zacks
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
GlobeNewswire
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the clearance of its Investigational